Developer docs
API playgroundTry for free, no card

Search company profiles

Generate Biomedicines

Full company profile

uuid000049i

Namestring
Generate Biomedicines
Legal namestring
Generate Biomedicines, Inc.
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Generate Biomedicines (Nasdaq: GENB) is a clinical-stage generative biology company founded in 2018 and incubated by Flagship Pioneering, headquartered in Somerville, Massachusetts with additional research operations in Andover. The company operates The Generate Platform, a continuous machine-learning-driven loop (Generate → Build → Measure → Learn) that integrates ML, biological engineering and medicine to design de novo protein therapeutics rather than screen or modify natural proteins. The platform's flagship technical asset is Chroma, a proprietary generative diffusion model for protein and protein-complex design that was published in Nature in 2023 and experimentally validated across 310 designed proteins (backbone RMSD ~1.0 Å versus crystal structures); Chroma code is open-sourced on GitHub with downloadable model weights. Four best-in-class CryoEM microscopes support high-throughput structural feedback, and the platform has cumulatively generated, built and tested more than 42,000 proteins.

The company's clinical pipeline is anchored by GB-0895, a long-acting anti-TSLP antibody for severe asthma (currently in two global Phase 3 trials enrolling ~1,600 patients, engineered for twice-yearly subcutaneous dosing) and a Phase 1 program in COPD. Other disclosed assets include GB-4362, an MMAE-neutralizing monoclonal antibody with FDA Fast Track designation intended for combination use with MMAE-based ADCs; GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer in a 50/50 collaboration with Roswell Park; and the deprioritized GB-0669 SARS-CoV-2 antibody (first-in-human data published on medRxiv, October 2025). GB-0895 is, per the company's own materials and third-party press, the first AI-derived antibody to enter Phase 3 clinical trials.

Generate Biomedicines generates revenue exclusively through enterprise R&D collaboration agreements with large pharmaceutical partners — chiefly Amgen (up to $1.9B total potential value across six programs since January 2022) and Novartis (up to $1B+ across multiple programs since September 2024) — recognizing $31.9M in collaboration revenue in FY2025 (up 56% YoY) and approximately $110M in cumulative collaboration payments to date. The company is pre-commercial with no product sales; it raised approximately $805M in private capital prior to its February 2026 Nasdaq IPO, which added $400M of gross proceeds and brought pro-forma cash to $516.6M as of March 31, 2026, supporting runway into the first half of 2028. Flagship Pioneering remains the largest shareholder at approximately 49% post-IPO.

Short descriptiontext

Generate Biomedicines is a clinical-stage biotech that uses its proprietary Chroma generative AI model and The Generate Platform to design de novo protein therapeutics, with lead asset GB-0895 (the first AI-derived antibody in Phase 3) for severe asthma. It monetizes via multi-program R&D collaborations with large pharma, notably Amgen (up to $1.9B) and Novartis (up to $1B+).

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSomerville, United States
HQ citystring
Somerville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
generative biology platform, AI protein design, therapeutic antibodies, drug discovery collaboration, clinical-stage biotechnology
Product category
AI-driven biologics drug discovery
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Collaboration revenue (pharma partnerships)
TypeLicensing Royalties
Description

Revenue recognized from R&D collaborations with major pharmaceutical partners under multi-target discovery agreements (Amgen — 6 programs since Jan 2022, up to $1.9B; Novartis — multiple discovery-stage programs since Sept 2024, up to $1B+). Generate reported $31.9 million in collaboration revenue for 2025, up 56% year-over-year, and has cumulatively received approximately $110 million in collaboration payments from Amgen and Novartis.

tradingview.com
2Equity capital and IPO proceeds
TypeSubscription Recurring
Description

Capital formation through venture financings (Series B $370M in Nov 2021; Series C $273M in 2023; cumulative ~$805M private financing) and IPO ($400M gross proceeds completed Feb 27, 2026 on NASDAQ under GENB at $16/share); cash position of $516.6M as of March 31, 2026 with runway projected into first half of 2028.

tradingview.com
3Future product sales (pre-commercial)
TypeOne Time License
Description

No commercial product revenue as of Q1 2026; clinical-stage company with lead asset GB-0895 in Phase 3 trials for severe asthma; revenue of $7.2M in Q1 2026 declined from $8.8M in Q1 2025, reflecting collaboration-driven business.

aijourn.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details2 tiers
1IPO public offering pricing
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Priced at $16.00 per share; 25 million shares offered; gross proceeds approximately $400 million; underwriters held 30-day option for additional 3,750,000 shares. Range originally filed at $15–$17 per share.

in.investing.com
2Pharma partnership / collaboration agreements
ModelOutcome Based/ PerformanceBilling cadenceMulti-year contract
Notes

Up to $1.9 billion deal value with Amgen (Jan 2022 announcement, expanded Jan 2024) across five/six programs; up to $1 billion-plus with Novartis (Sept 2024) for protein therapeutics. Specific per-program pricing is not publicly disclosed.

fiercebiotech.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Generate:Chroma
Description

A generative model for protein design that creates new protein molecules based on geometric and functional programming instructions.

generatebiomedicines.com
+2 more records
Core offering1 text field

Generate Biomedicines operates a generative biology platform that uses machine learning (the Chroma diffusion model) to design de novo protein therapeutics rather than screening or modifying natural proteins. The company sells its discovery and development capabilities through multi-program enterprise collaborations with large pharmaceutical partners (Amgen, Novartis) and is advancing its own clinical-stage pipeline, including the Phase 3 anti-TSLP antibody GB-0895 for severe asthma and earlier-stage candidates in oncology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • First AI-derived antibody (GB-0895) progressed from concept to Phase 3 trials in five years
+7 more records
Product overview1 text field

Generate Biomedicines operates a single integrated generative biology platform with multiple clinical-stage therapeutic candidates as outputs. The architecture centers on The Generate Platform, an AI-driven continuous generate-build-measure-learn loop underpinned by the Generative Biology methodology and the proprietary Chroma generative protein model. Platform outputs feed a pipeline of protein-based therapeutic candidates including the Phase 3 anti-TSLP antibody GB-0895 (lead asset for severe asthma, with a Phase 1 program in COPD), the Phase 1 MMAE-neutralizing antibody GB-4362 (FDA Fast Track designated), the preclinical IL-18 armored CAR T-cell therapy GB-5267 (MUC16, partnered with Roswell Park), and additional confidential preclinical programs including next-generation ADCs. The platform also supports strategic platform collaborations with Amgen (six programs, since January 2022) and Novartis (multiple programs, since September 2024).

Product and service6 records
1The Generate Platform
CategoryGenerative biology platform
2Chroma
CategoryGenerative AI model
3GB-0895
CategoryClinical-stage therapeutic candidate
4GB-4362
CategoryClinical-stage therapeutic candidate
5GB-5267
CategoryPreclinical therapeutic candidate
6GB-0669
CategoryClinical-stage therapeutic candidate (deprioritized)
Scale indicator18 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-09-01
Description

Multi-program discovery collaboration announced September 2024 across multiple discovery-stage protein therapeutics programs; total potential deal value exceeds $1 billion per company and Klover analysis. Generate and Novartis publicly disclosed the collaboration across multiple industry sources.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Multi-program protein therapeutics collaboration originally announced January 2022 for five programs and expanded in January 2024 to add a sixth program; total potential deal value of up to $1.9 billion across six programs. Collaboration revenue is included in the cumulative $110M received from Amgen/Novartis referenced at IPO. Generate and Amgen publicly disclosed the collaboration through the IPO S-1 and corporate filings.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

50/50 collaboration on GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer. IND 'study may proceed' granted December 2025; first patient dosing planned for H2 2026 per Morgan Stanley analyst coverage and pipeline page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic collaboration in oncology and CAR-T cells announced 2023 to develop novel therapeutics by combining Generate's generative AI platform with MD Anderson's translational and clinical research capabilities.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Founding incubator and largest shareholder; founded Generate in 2018. Flagship Pioneering holds approximately 48.76% post-IPO via Noubar Afeyan and remains a 57% pre-IPO shareholder; board chair Noubar Afeyan (Founder/CEO of Flagship) plus Flagship partners Paul Parker and Rupert Vessey sit on Generate's board. Generated >$750M prior to IPO across multiple financing rounds.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Affiliation via board director Stéphane Bancel (CEO of Moderna and Flagship Pioneering venture partner). No commercial partnership is publicly disclosed.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining generative models, biology and chemistry to identify novel targets and design small molecules; one of the most prominent and well-funded generative biology peers to Generate, pursuing a comparable pharma BD and pipeline strategy.

TypeDirect peer
Description

Clinical-stage AI-enabled biotech combining high-throughput wet-lab experimentation with ML to discover and develop therapeutics; directly comparable as a publicly-traded AI drug-discovery platform with both pipeline assets and large pharma partnerships (e.g., Roche, Bayer).

TypeDirect peer
Description

Physics-based computational platform for molecular design combining ML with simulation for drug and materials discovery; operates a hybrid software-plus-co-discovery business model with big-pharma collaborations, comparable to Generate's platform-plus-partnership GTM.

4Isomorphic Labs
TypeDirect peer
Description

Alphabet-founded AI drug discovery company building on DeepMind's AlphaFold to design novel therapeutics; closest large-cap peer pursuing generative protein/small-molecule design with major pharma partnerships (Eli Lilly, Novartis).

TypeDirect peer
Description

Generative AI drug creation company combining a proprietary E. coli-based synthetic biology platform with deep learning models for antibody and protein therapeutic design; a direct platform competitor in AI-designed biologics with pharma collaborations.

TypeEmerging player
Description

Well-funded (>$1B launch) AI drug discovery company founded in 2023 leveraging generative models to design therapeutics; comparable as a recent entrant with similar ambitions and large capital base pursuing generative biology for protein and small molecule discovery.

TypeEmerging player
Description

AI-driven protein engineering company building generative models for designing new proteins, with partnerships including Novo Nordisk; comparable as an emerging generative-protein-design peer pursuing a similar BD-plus-platform strategy.

TypeEmerging player
Description

AI protein design company founded by protein-ML researchers applying large language models to protein engineering, with a focus on gene editing and therapeutics; comparable as a frontier generative-protein-design peer with adjacent use cases.

TypeEmerging player
Description

AI-enabled drug discovery company combining single-cell genomics, graph ML and lab-in-the-loop experimentation to discover novel therapeutics; comparable as a wet-lab-and-ML platform biotech pursuing similar indication-agnostic discovery partnerships.

TypeEmerging player
Description

Frontier AI research company building large-scale models for biology and protein design (ESM3); comparable as a foundational generative-protein-model peer with ambitions spanning therapeutic and non-therapeutic protein design.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration7 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Generate Biomedicines

AI-driven biologics drug discoverygeneratebiomedicines.com

Generate Biomedicines is a clinical-stage biotech that uses its proprietary Chroma generative AI model and The Generate Platform to design de novo protein therapeutics, with lead asset GB-0895 (the first AI-derived antibody in Phase 3) for severe asthma. It monetizes via multi-program R&D collaborations with large pharma, notably Amgen (up to $1.9B) and Novartis (up to $1B+).

What Generate Biomedicines does

Generate Biomedicines (Nasdaq: GENB) is a clinical-stage generative biology company founded in 2018 and incubated by Flagship Pioneering, headquartered in Somerville, Massachusetts with additional research operations in Andover. The company operates The Generate Platform, a continuous machine-learning-driven loop (Generate → Build → Measure → Learn) that integrates ML, biological engineering and medicine to design de novo protein therapeutics rather than screen or modify natural proteins. The platform's flagship technical asset is Chroma, a proprietary generative diffusion model for protein and protein-complex design that was published in Nature in 2023 and experimentally validated across 310 designed proteins (backbone RMSD ~1.0 Å versus crystal structures); Chroma code is open-sourced on GitHub with downloadable model weights. Four best-in-class CryoEM microscopes support high-throughput structural feedback, and the platform has cumulatively generated, built and tested more than 42,000 proteins.

The company's clinical pipeline is anchored by GB-0895, a long-acting anti-TSLP antibody for severe asthma (currently in two global Phase 3 trials enrolling ~1,600 patients, engineered for twice-yearly subcutaneous dosing) and a Phase 1 program in COPD. Other disclosed assets include GB-4362, an MMAE-neutralizing monoclonal antibody with FDA Fast Track designation intended for combination use with MMAE-based ADCs; GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer in a 50/50 collaboration with Roswell Park; and the deprioritized GB-0669 SARS-CoV-2 antibody (first-in-human data published on medRxiv, October 2025). GB-0895 is, per the company's own materials and third-party press, the first AI-derived antibody to enter Phase 3 clinical trials.

Generate Biomedicines generates revenue exclusively through enterprise R&D collaboration agreements with large pharmaceutical partners — chiefly Amgen (up to $1.9B total potential value across six programs since January 2022) and Novartis (up to $1B+ across multiple programs since September 2024) — recognizing $31.9M in collaboration revenue in FY2025 (up 56% YoY) and approximately $110M in cumulative collaboration payments to date. The company is pre-commercial with no product sales; it raised approximately $805M in private capital prior to its February 2026 Nasdaq IPO, which added $400M of gross proceeds and brought pro-forma cash to $516.6M as of March 31, 2026, supporting runway into the first half of 2028. Flagship Pioneering remains the largest shareholder at approximately 49% post-IPO.

Generate Biomedicines firmographics

Firmographics
Name
Generate Biomedicines
Legal name
Generate Biomedicines, Inc.
Website
https://generatebiomedicines.com
Company type
Public
Founded year
2018
Operating status
Ipo
Headcount range
251–500 employees
Short description
Generate Biomedicines is a clinical-stage biotech that uses its proprietary Chroma generative AI model and The Generate Platform to design de novo protein therapeutics, with lead asset GB-0895 (the first AI-derived antibody in Phase 3) for severe asthma. It monetizes via multi-program R&D collaborations with large pharma, notably Amgen (up to $1.9B) and Novartis (up to $1B+).
Ownership category
akta.pro rank

Where Generate Biomedicines is headquartered

Location

Headquarters

HQ city
Somerville
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Generate Biomedicines business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Collaboration revenue (pharma partnerships): Revenue recognized from R&D collaborations with major pharmaceutical partners under multi-target discovery agreements (Amgen — 6 programs since Jan 2022, up to $1.9B; Novartis — multiple discovery-stage programs since Sept 2024, up to $1B+). Generate reported $31.9 million in collaboration revenue for 2025, up 56% year-over-year, and has cumulatively received approximately $110 million in collaboration payments from Amgen and Novartis.
  2. Equity capital and IPO proceeds: Capital formation through venture financings (Series B $370M in Nov 2021; Series C $273M in 2023; cumulative ~$805M private financing) and IPO ($400M gross proceeds completed Feb 27, 2026 on NASDAQ under GENB at $16/share); cash position of $516.6M as of March 31, 2026 with runway projected into first half of 2028.
  3. Future product sales (pre-commercial): No commercial product revenue as of Q1 2026; clinical-stage company with lead asset GB-0895 in Phase 3 trials for severe asthma; revenue of $7.2M in Q1 2026 declined from $8.8M in Q1 2025, reflecting collaboration-driven business.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractIPO public offering pricing
Outcome Based/ PerformanceMulti-year contractPharma partnership / collaboration agreements

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Generate Biomedicines product offering

Product offering

Core offering

Generate Biomedicines operates a generative biology platform that uses machine learning (the Chroma diffusion model) to design de novo protein therapeutics rather than screening or modifying natural proteins. The company sells its discovery and development capabilities through multi-program enterprise collaborations with large pharmaceutical partners (Amgen, Novartis) and is advancing its own clinical-stage pipeline, including the Phase 3 anti-TSLP antibody GB-0895 for severe asthma and earlier-stage candidates in oncology.

Product overview

Generate Biomedicines operates a single integrated generative biology platform with multiple clinical-stage therapeutic candidates as outputs. The architecture centers on The Generate Platform, an AI-driven continuous generate-build-measure-learn loop underpinned by the Generative Biology methodology and the proprietary Chroma generative protein model. Platform outputs feed a pipeline of protein-based therapeutic candidates including the Phase 3 anti-TSLP antibody GB-0895 (lead asset for severe asthma, with a Phase 1 program in COPD), the Phase 1 MMAE-neutralizing antibody GB-4362 (FDA Fast Track designated), the preclinical IL-18 armored CAR T-cell therapy GB-5267 (MUC16, partnered with Roswell Park), and additional confidential preclinical programs including next-generation ADCs. The platform also supports strategic platform collaborations with Amgen (six programs, since January 2022) and Novartis (multiple programs, since September 2024).

Differentiator

Problem solved

Functional benefit

Brands

  • Generate:Chroma: A generative model for protein design that creates new protein molecules based on geometric and functional programming instructions.
  • Generative Biology®
  • The Generate Platform™

Products and services

  • The Generate Platform
  • Chroma
  • GB-0895
  • GB-4362
  • GB-5267
  • GB-0669

Quantifiable outcome

  • First AI-derived antibody (GB-0895) progressed from concept to Phase 3 trials in five years
  • +7 more outcomes

Companies that use Generate Biomedicines

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Generate Biomedicines technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability4 records

Feature6 records

Generate Biomedicines partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

  • NovartisflagshipStrategic or Co-development Partner · 1 September 2024Multi-program discovery collaboration announced September 2024 across multiple discovery-stage protein therapeutics programs; total potential deal value exceeds $1 billion per company and Klover analysis. Generate and Novartis publicly disclosed the collaboration across multiple industry sources.
  • AmgenflagshipStrategic or Co-development Partner · 1 January 2022Multi-program protein therapeutics collaboration originally announced January 2022 for five programs and expanded in January 2024 to add a sixth program; total potential deal value of up to $1.9 billion across six programs. Collaboration revenue is included in the cumulative $110M received from Amgen/Novartis referenced at IPO. Generate and Amgen publicly disclosed the collaboration through the IPO S-1 and corporate filings.
  • Roswell Park Comprehensive Cancer CentercoreStrategic or Co-development Partner50/50 collaboration on GB-5267, an IL-18 armored CAR T-cell therapy targeting MUC16 for metastatic ovarian cancer. IND 'study may proceed' granted December 2025; first patient dosing planned for H2 2026 per Morgan Stanley analyst coverage and pipeline page.
  • MD Anderson Cancer CentercoreStrategic or Co-development PartnerStrategic collaboration in oncology and CAR-T cells announced 2023 to develop novel therapeutics by combining Generate's generative AI platform with MD Anderson's translational and clinical research capabilities.
  • Flagship PioneeringflagshipStrategic or Co-development PartnerFounding incubator and largest shareholder; founded Generate in 2018. Flagship Pioneering holds approximately 48.76% post-IPO via Noubar Afeyan and remains a 57% pre-IPO shareholder; board chair Noubar Afeyan (Founder/CEO of Flagship) plus Flagship partners Paul Parker and Rupert Vessey sit on Generate's board. Generated >$750M prior to IPO across multiple financing rounds.
  • ModernaminorStrategic or Co-development PartnerAffiliation via board director Stéphane Bancel (CEO of Moderna and Flagship Pioneering venture partner). No commercial partnership is publicly disclosed.

Scale indicators18 records

Recent moves7 records

Expansion highlights6 records

Generate Biomedicines competitors and assessment

Company assessment

Direct peers

  • Insilico Medicine: AI-driven drug discovery company combining generative models, biology and chemistry to identify novel targets and design small molecules; one of the most prominent and well-funded generative biology peers to Generate, pursuing a comparable pharma BD and pipeline strategy.
  • Recursion Pharmaceuticals: Clinical-stage AI-enabled biotech combining high-throughput wet-lab experimentation with ML to discover and develop therapeutics; directly comparable as a publicly-traded AI drug-discovery platform with both pipeline assets and large pharma partnerships (e.g., Roche, Bayer).
  • Schrödinger: Physics-based computational platform for molecular design combining ML with simulation for drug and materials discovery; operates a hybrid software-plus-co-discovery business model with big-pharma collaborations, comparable to Generate's platform-plus-partnership GTM.
  • Isomorphic Labs: Alphabet-founded AI drug discovery company building on DeepMind's AlphaFold to design novel therapeutics; closest large-cap peer pursuing generative protein/small-molecule design with major pharma partnerships (Eli Lilly, Novartis).
  • Absci: Generative AI drug creation company combining a proprietary E. coli-based synthetic biology platform with deep learning models for antibody and protein therapeutic design; a direct platform competitor in AI-designed biologics with pharma collaborations.

Emerging players

  • Xaira Therapeutics: Well-funded (>$1B launch) AI drug discovery company founded in 2023 leveraging generative models to design therapeutics; comparable as a recent entrant with similar ambitions and large capital base pursuing generative biology for protein and small molecule discovery.
  • Cradle Bio: AI-driven protein engineering company building generative models for designing new proteins, with partnerships including Novo Nordisk; comparable as an emerging generative-protein-design peer pursuing a similar BD-plus-platform strategy.
  • Profluent Bio: AI protein design company founded by protein-ML researchers applying large language models to protein engineering, with a focus on gene editing and therapeutics; comparable as a frontier generative-protein-design peer with adjacent use cases.
  • Relation Therapeutics: AI-enabled drug discovery company combining single-cell genomics, graph ML and lab-in-the-loop experimentation to discover novel therapeutics; comparable as a wet-lab-and-ML platform biotech pursuing similar indication-agnostic discovery partnerships.
  • EvolutionaryScale: Frontier AI research company building large-scale models for biology and protein design (ESM3); comparable as a foundational generative-protein-model peer with ambitions spanning therapeutic and non-therapeutic protein design.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Generate Biomedicines social profiles

Digital presence

Generate Biomedicines compliance and trust

Trust signal

Compliance3 records

Generate Biomedicines financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Generate Biomedicines leadership team

Management profile

Number of profiles

Profiles21 records

Generate Biomedicines funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Generate Biomedicines M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Generate Biomedicines

What does Generate Biomedicines do?

Generate Biomedicines operates a generative biology platform that uses machine learning (the Chroma diffusion model) to design de novo protein therapeutics rather than screening or modifying natural proteins. The company sells its discovery and development capabilities through multi-program enterprise collaborations with large pharmaceutical partners (Amgen, Novartis) and is advancing its own clinical-stage pipeline, including the Phase 3 anti-TSLP antibody GB-0895 for severe asthma and earlier-stage candidates in oncology.

Is Generate Biomedicines a public or private company?

Generate Biomedicines is a public company. It is classified as public and is currently ipo.

When was Generate Biomedicines founded?

Generate Biomedicines was founded in 2018. It employs 251 to 500 people.

Where is Generate Biomedicines based?

Generate Biomedicines is headquartered in Somerville, United States, in the North America region.

How does Generate Biomedicines make money?

Three revenue lines are on record. Collaboration revenue (pharma partnerships) is the primary driver. The others are equity capital and IPO proceeds and future product sales (pre-commercial).

Who are Generate Biomedicines's main competitors?

Direct peers on record are Insilico Medicine, Recursion Pharmaceuticals, Schrödinger, Isomorphic Labs and Absci. Emerging players are Xaira Therapeutics, Cradle Bio, Profluent Bio, Relation Therapeutics and EvolutionaryScale.

Does Generate Biomedicines have an API?

No public API is recorded for Generate Biomedicines.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeGENERATE BIOMEDICINES ($GENB) Releases Q3 2026 Earnings | GENB Stock NewsGenerate Biomedicines reported Q3 2026 earnings of -$0.68 per share, missing estimates by $0.11, and revenue of $4.22 million, missing estimates by $3.69 million. Insiders sold 11,409 shares, and 73 institutional investors added positions while 25 reduced them.MarketScreenerGenerate Biomedicines Q3 Loss Narrows, Revenue FallsGenerate Biomedicines reported a Q3 net loss of $0.68 per share, beating the $0.56 loss estimated by FactSet. Revenue fell in the quarter, though the exact amount was not disclosed. The company's stock closed at $13.49, down 2.10%.The future of tradingGenerate Biomedicines Q3 net loss widens 46% year over year to $87.7 million; Q3 revenue falls 56% year over year to $4.2 millionGenerate Biomedicines reported a Q3 2026 net loss of $87.7 million, up 46% year-over-year, with revenue falling 56% to $4.2 million. R&D expenses rose 32% to $82.3 million, driven by GB-0895 Phase 3 severe asthma trials. Cash and marketable securities totaled $404.2 million, with a projected runway into the first half of 2028.YahooGenerate Biomedicines: Q3 Earnings SnapshotGenerate Biomedicines reported a Q3 loss of $87.7 million, or 68 cents per share, missing analyst estimates. Revenue of $4.2 million also fell short of the $8.2 million expected by three analysts.Business & FinancialGenerate Biomedicines Reports Third Quarter 2026 Financial Results And Provides Business UpdateGenerate Biomedicines reported Q3 2026 revenue of $4.2 million and a net loss of $87.7 million, with cash of $404.2 million. The company announced a $30 million upfront collaboration with Zealand Pharma and a research partnership with Anthropic on CAR T-cell research.TradingViewGenerate Biomedicines Reports $87.7 Million Q3 Loss, $404.2 Million in CashGenerate Biomedicines reported Q3 2026 revenue of $4.2 million and a net loss of $87.7 million, down from $9.6 million and $60.0 million a year earlier. Cash, cash equivalents, and marketable securities totaled $404.2 million at September 30, 2026. The company expects these resources, plus a $30 million Zealand Pharma upfront payment, to fund operations into the first half of 2028.GlobeNewswireGenerate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business UpdateGenerate Biomedicines reported Q3 2026 results with a $87.7 million net loss and $4.2 million revenue. The company also announced a $30 million upfront collaboration with Zealand Pharma and first-patient dosing of GB-5267 in ovarian cancer.American Banking and Market NewsGenerate Biomedicines Inc $GENB Stock: CenterBook Partners LP Decreases PositionCenterBook Partners LP cut its stake in Generate Biomedicines by 67% in Q3, selling 88,187 shares and leaving with 43,373 shares worth $651,000. Other institutions like Braidwell LP and Banque Pictet & Cie also bought new positions, while Sumitomo Mitsui Trust Group increased holdings by 103.1%.American Banking and Market NewsMonte Rosa Therapeutics (NASDAQ:GLUE) vs. Generate Biomedicines (NASDAQ:GENB) Head-To-Head ContrastMonte Rosa Therapeutics and Generate Biomedicines are compared on ratings, profitability, and valuation. Monte Rosa has a higher consensus target price ($26.44 vs $26.40) and beats Generate on 10 of 14 factors, including higher revenue and earnings. Analysts favor Monte Rosa due to stronger ratings and upside.Investing.comGenerate Biomedicines at guggenheim conference: speed over cautionGenerate Biomedicines presented its pipeline at the Guggenheim conference, with lead asthma program SOLAIRIA now in Phase III after skipping Phase II. The company has five molecules in clinical development and a cash runway into early 2028, while exploring additional capital options.